Reaching Others University at Buffalo - The State University of New York
Skip to Content
Brahm                          Segal

Brahm H. Segal MD

Department of Medicine

Professor; Vice Chair, Faculty Development

Specialty/Research Focus

Infectious Diseases; Oncology

 
top-left cornertop-right corner
Professional Summary:

I care for hospitalized patients and outpatients at Roswell Park Cancer Institute (RPCI), where I am head of Infectious Diseases. My area of clinical expertise relates to infections in patients with cancer and stem cell transplant recipients, and I have served on several national panels that establish guidelines for preventing, diagnosing, and managing infections in these patients. I also have a specific interest in patients with primary phagocytic disorders (e.g., chronic granulomatous disease).

RPCI is the site of my clinical teaching. I also teach medical students in lecture settings and in small group sessions in their first and second years, including courses in lung pathophysiology and microbiology-immunology. We intermittently have students in our lab and participate in a grant designed to encourage medical students to become physician-scientists.

I mentor residents in their clinical training and in research. I also teach fellows in all aspects of their training and mentor those who perform their research projects in my lab.

I have an active, nationally funded translational research program. The major focus of our lab is studying NADPH oxidase as a critical regulator of inflammation and host defense. NADPH oxidase is an emergency host defense pathway that is rapidly activated in response to certain microbial products, and converts molecular oxygen to superoxide anion and downstream reactive oxidant intermediates (ROIs). Chronic granulomatous disease is an inherited disorder of the NADPH oxidase characterized by severe bacterial and fungal infections (e.g., invasive aspergillosis) and by excessive inflammation. In addition to its critical host defense role, our lab, in collaboration with colleagues, found that NADPH oxidase also functions to restrain inflammation by modulating redox-sensitive innate immune pathways. NADPH oxidase also affects T-cell responses, including the balance between Tn17 and regulatory T-cells. We have an NIH grant to further elucidate mechanisms by which NADPH oxidase regulates inflammation.

We believe that our work has broad relevance to human diseases associated with inflammation, such as inflammation-induced injury and tumor immunology. Indeed, several of the pathways that NADPH oxidase regulates are important in tumorigenesis and the tumor microenvironment (e.g., NF-kB, Nrf2, IL-17, Tregs), and are potential therapeutic targets. In collaboration with colleagues, we are examining how NADPH oxidase influences tumor immunity.

Education and Training:
  • Fellowship, Infectious Diseases, National Institute of Allergy and Infectious Diseases (1999)
  • Residency, Medicine, Tufts New England Medical Center (1995)
  • MD, Albert Einstein College of Medicine (1992)
Employment:
  • Professor, Roswell Park Cancer Institute (2001-present)
Awards and Honors:
  • Top Doctors (2011)
  • Best Doctors (2011)
  • Fellow, Infectious Diseases Society of America (2007)
  • Fellow, American College of Physicians (2005)
  • SUNY at Buffalo Department of Medicine Award for Teaching (2001)

Research Expertise:
  • Clinical studies of infectious diseases in patients with cancer: I am head of Infectious Diseases at Roswell Park Cancer Institute. My area of clinical expertise relates to infections in patients with cancer and stem cell transplant recipients. I have served on several national panels (e.g., NCCN, IDSA, CDC) that establish guidelines for preventing, diagnosing, and managing infections in these patients. I also have a specific interest in patients with primary phagocytic disorders (e.g., chronic granulomatous disease)
Grants and Sponsored Research:
  • February 2009–January 2014
    Role of NADPH Oxidase in Regulating Inflammation
    NIH
    Role: Principal Investigator
    $2,176,043
  • June 2012–June 2013
    Overcoming Myeloid Cell-Mediated Immunosuppression in Epithelial Ovarian Cancer
    Roswell Park Cancer Institute Tumor Immunology and Immunotherapy Program
    Role: Principal Investigator
    $30,000
  • May 2012–May 2013
    Role of NADPH Oxidase in Ataxia Telangiectasia-Related Tumorigenesis
    Wilmot Cancer Center / Roswell Park Cancer Institute pilot fund initiative
    Role: Co-Principal Investigator
    $100,000
  • April 2012–April 2013
    Overcoming Myeloid Cell-Mediated Immunosuppression to Enhance Vaccine Efficacy in Ovarian Cancer
    Pilot & Collaborative Studies for Clinical & Translational Research, Buffalo Clinical and Translational Center.
    Role: Principal Investigator
    $34,000

Evaluative Studies and Case Reports:
See All (11 Total) >
Journal Articles:
See All (66 Total) >
Abstracts:
  • Smiley S, Almyroudis N, Segal BH. Epidemiology and management of opportunistic infections in immunocompromised patients with cancer.. Hematology & Oncology. 2005; 8(3).

Presentations:
  • "NADPH oxidase limits inflammation and injury in aspiration-induced acute lung injury" American Thoracic Society (ATS) International Conference, American Thoracic Society (ATS) (2011)
  • "Nrf2 is Protective in Neutrophil-mediated Acute Lung Injury" American Thoracic Society (ATS) International Conference, American Thoracic Society (ATS) (2011)
  • "Clinical Presentation and Non-BMT Management of Patients with CGD: New Approaches" American Society of Blood and Marrow Transplantation (ASBMT),, American Society of Blood and Marrow Transplantation (ASBMT),, Chronic Granulomatous Disease (CGD): Lessons From a Rare Disorder (2011)
  • "Immune System and Management of Aspergillosis" 12th Japan Mycoses Forum (2011)
  • "NADPH Oxidase: a Master Regulator of Antifungal Host Defense and Inflammation" Gordon Research Conference, Gordon Research Conference (2011)
  • "Immunity against Aspergillosis and Aspergillus-associated Diseases" 2nd Shanghai Oriental Respiratory Disease International Forum (2010)
  • "Treatment of Aspergillosis: 2008 Guidelines of IDSA and Clinical Practice" 2nd Shanghai Oriental Respiratory Disease International Forum (2010)
  • "Aspergillosis" New York State Thoracic Society Annual Scientific Assembly, New York State Thoracic Society (2010)
  • "Conventional and novel risk factors for invasive aspergillosis" 20th Focus on Fungal Infections (2010)
  • "Sunday Brunch with the Experts: Management of Treatment-related Infections, Thromboses, and Neuropathy" National Comprehensive Cancer Network 15th Annual Conference: Clinical Practice Guidelines & Quality Care,, NCCN (2010)
  • "Aspergillosis in chronic granulomatous diseases" 4th Advances Against Aspergillosis (2010)
  • "NADPH oxidase and inflammation" 4th Advances Against Aspergillosis (2010)
See All (12 Total) >
Service Activities:
  • School of Medicine & Biomedical Sciences Unqualified Promotions; Member (2011)

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

bottom-left cornerbottom-right corner

Contact Information

Roswell Park Cancer Institute
Elm & Carlton Streets
Buffalo, NY 14263
Phone: (716) 845-5721
Fax: (716) 845-5777
Email: bhsegal@buffalo.edu

Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB School of Medicine and Biomedical Sciences.

View this faculty on UBMD

Log in to Update Your Profile
"); pageTracker._trackPageview();